1. p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton. Fuertes-Alvarez S, Maeso-Alonso L, Villoch-Fernandez J, Wildung M, Martin-Lopez M, Marshall C, Villena-Cortes AJ, Diez-Prieto I, Pietenpol JA, Tissir F, Lizé M, Marques MM, Marin MC (2018) Cell Death Dis 9(12): 1183
    › Primary publication · 30518789 (PubMed) · PMC6281643 (PubMed Central)
  2. p73 Is Required for pIgR Expression in the Respiratory Epithelium. Richmond BW, Du RH, Marshall C, Pietenpol J, Polosukhin VV, Blackwell TS (2018) Ann Am Thorac Soc 15(Supplement_4): S290
    › Primary publication · 30759000 (PubMed) · PMC6322007 (PubMed Central)
  3. p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA (2018) iScience : 236-249
    › Primary publication · 30340069 (PubMed) · PMC6197761 (PubMed Central)
  4. Corrigendum to "Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control". Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y (2017) Biomed Res Int : 7409598
    › Primary publication · 28804721 (PubMed) · PMC5540237 (PubMed Central)
  5. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD (2017) BMC Cancer 17(1): 241
    › Primary publication · 28376728 (PubMed) · PMC5379658 (PubMed Central)
  6. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA (2017) Clin Cancer Res 23(15): 4035-4045
    › Primary publication · 28270498 (PubMed) · PMC5540799 (PubMed Central)
  7. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) PLoS One 11(6): e0157368
    › Primary publication · 27310713 (PubMed) · PMC4911051 (PubMed Central)
  8. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA (2016) Cell Rep 14(10): 2289-300
    › Primary publication · 26947080 (PubMed) · PMC4794398 (PubMed Central)
  9. Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. Zhang P, Samuels DC, Lehmann B, Stricker T, Pietenpol J, Shyr Y, Guo Y (2016) Brief Bioinform 17(2): 224-32
    › Primary publication · 26249222 (PubMed) · PMC5974936 (PubMed Central)
  10. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS (2016) BMC Cancer : 143
    › Primary publication · 26908167 (PubMed) · PMC4763445 (PubMed Central)